US biopharma AbbVie has signed an agreement to acquire US biotechnology company Nimble Therapeutics, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases.
At an investor update at the end of last week, Lonza has announced its "One Lonza" restructuring strategy, which aims to reorganize its CDMO business, simplify its operating model, enhance manufacturing and engineering, and expand its production footprint.
Clariant is expanding its Cangzhou production site to manufacture the multifunctional additive Nylostab S-EED.
Danish drugmaker Novo Nordisk plans to invest 8.5 billion Danish kroner (about €1.14 billion) to establish a new production facility in Odense, Denmark.
Italian drugmaker Newron Pharmaceuticals and EA Pharma, a subsidiary of Japan’s Eisai, today have entered into a license agreement to develop, manufacture and commercialize Newron’s evenamide in Japan and other designated Asian territories.
An Attractive and Highly Sought-after Business Location
The life sciences sector, encompassing biotechnology, pharmaceuticals and medical technology, is developing rapidly in Austria.
The Italian Olon Group, a leading international supplier of active pharmaceutical ingredients (APIs), presents the 2023 Corporate Sustainability Report and confirms the sustainability journey toward energy transition, investments in alternative energy sources, social and economic involvement and support for the communities in which it operates
Ineos and its partners Harbour Energy and Nordsøfonden have taken the final investment decision (FID) into the first commercial phase ‘Greensand Future’ with storage operations in a depleted oil field in the Danish North Sea set to begin at the end of 2025/early 2026.
French biotechnology company Samabriva has opened a new 1,400 m2 biomanufacturing facility in Liege, Belgium. The multi-million Euros investment is designed to provide industrial-scale production of high-value natural molecules used in the manufacture of pharmaceutical products, the company said.
In a move to expand its global biomanufacturing network, US biopharma Amgen is planning to invest $1 billion to build a second drug substance manufacturing facility at its US site in Holy Springs, North Carolina. This brings the company's total planned investment in Holly Springs to more than $1.5 billion, building on its previously announced $550 million commitment.
In 2024, the chemical distribution industry is at a pivotal moment, navigating both challenges and new opportunities. As distributors grapple with a landscape shaped by shifting global trade routes, demand constraints, and digital disruption, their roles are evolving far beyond traditional bulk breaking.
Plastics are highly effective but environmentally damaging. PET is a prime example, being cheap and recyclable yet oil-based. With plastics set to consume 20% of global oil and gas by 2050, sustainable alternatives are crucial. Enter PEF, a bioplastic that could revolutionize the industry. Can PEF be the solution we need?
The EU's Corporate Sustainability Due Diligence Directive (CSDDD) is reshaping the chemical industry's approach to environmental and social responsibility. A close look at the requirements reveals significant changes to supply chain oversight, risk management, and sustainability reporting. Chemical companies must implement new strategies to ensure compliance, drive innovation, and adapt to evolving regulations.
Experts of Ataman Chemicals, Barentz, Biesterfeld, Brenntag, BÜFA Chemicals, CSC Jaeklechemie, Häffner, IMCD, Krahn Chemie, Möller Chemie, Nordmann, RN Chemicals, and Stockmeier share their opinions
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Interview with Olli Kähkönen, Nordic Bioproducts Group
Interview with Franziska Walde and Lukas Fischer, Refinq
Dorothee Arns, Director General of FECC, discusses current challenges, market trends and her vision for the chemical distribution industry in Europe.
Today, economic success is defined by a different perception and practice of supply capability and supply security. This applies not only to the European trade with chemicals but to the entire chemical value chain.
The Society of Chemical Manufacturers & Affiliates (SOCMA) has published the results of its 2025 Contract Manufacturing Outlook survey which reveals significant trends and insights into the contract manufacturing landscape.
Dow recently announced that Karen S. Carter, currently president of Dow Packaging & Specialty Plastics, has been appointed to the role of Chief Operating Officer, effective immediately.
US drug manufacturer Eli Lilly announced a $3 billion expansion of its US manufacturing facility in Kenosha County, Wisconsin, that the company acquired earlier this year. This investment will extend the company's global parenteral (injectable) product manufacturing network for diabetes, obesity and future medicines across therapeutic areas.
